Twist Bioscience Corporation (FRA:0ME)
Germany · Delayed Price · Currency is EUR | Market Cap | 9.13B +564.7% |
| Revenue (ttm) | 377.95M +19.2% |
| Net Income | -119.67M |
| EPS | -1.95 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 133.30 |
| Previous Close | 135.65 |
| Day's Range | 133.05 - 133.30 |
| 52-Week Range | 21.69 - 135.65 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 13, 2026 |
About Twist Bioscience
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. It offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglo... [Read more]
Financial Performance
In fiscal year 2025, Twist Bioscience's revenue was $376.57 million, an increase of 20.32% compared to the previous year's $312.97 million. Losses were -$77.67 million, -62.79% less than in 2024.
Financial numbers in USD Financial StatementsNews
Twist Bioscience Joins Lilly TuneLab to Advance Antibody Drug Discovery
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced an agreement with Lilly TuneLab, a collaborative ...
Twist Bioscience Transcript: 2026 Global Healthcare Conference
Miniaturized DNA synthesis technology is driving rapid growth, with expanding applications in diagnostics and therapeutics. AI-driven drug discovery and data services are key growth drivers, supported by strong customer demand and strategic partnerships. Profitability is targeted for Q4, with long-term plans for sustained high growth and margin expansion.
AI & Robotics in 2026: 16 Recent Developments for Investors
If AI and robotics suddenly feel like they are moving faster, August gave investors plenty of evidence that the pace really is accelerating. We saw longer-running agents, faster and cheaper inference,...
Twist Bioscience to Present at Baird 2026 Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder...
Twist Bioscience Announces Pricing of Upsized $300.0 Million Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (Nasdaq: TWST) (“Twist”), a mid-cap growth and value biotech company, today announced the pricing of an upsized underwritten ...
Twist Bioscience Announces Proposed Public Offering of $250.0 Million of Common Stock
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (Nasdaq: TWST) (“Twist”), a mid-cap growth and value biotech company, today announced the commencement of an underwritten pub...
Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a mid-cap growth and value bi...
Twist Bioscience Earnings Call Transcript: Q3 2026
Record Q3 revenue grew 23% year-over-year, driven by strong demand in AI-enabled drug discovery and diagnostics. Raised fiscal 2026 guidance, expecting 21% annual growth and adjusted EBITDA breakeven in Q4. Triple-digit AI order growth is projected to continue into 2027.
Twist Bioscience Slides: Q3 2026
Twist Bioscience has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on August 3, 2026.
Twist Bioscience Earnings release: Q3 2026
Twist Bioscience released its Q3 2026 earnings on August 3, 2026, summarizing the period's financial results.
Twist Bioscience Quarterly report: Q3 2026
Twist Bioscience has published its Q3 2026 quarterly earnings report on August 3, 2026.
Twist Bioscience Announces Fiscal 2026 Third Quarter Financial Results
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced financial results and business highlights for the...
Twist Bioscience to Report Fiscal 2026 Third Quarter Financial Results on Monday, August 3, 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that it will issue its financial results for the ...
Ozempic Linked To Lower Risk Of Violence In New Study
The researchers said the findings are not causal and urged more research into whether GLP-1s reduce the risk of violence. Daniel Semenza, lead author of the study and director of research at the New J...
Twist Bioscience Transcript: 46th Annual William Blair Growth Stock Conference
The company leverages silicon-based DNA synthesis to deliver rapid innovation, automation, and cost reductions, driving strong revenue growth and expanding its addressable market. With a diversified product portfolio and customer base, it targets adjusted EBITDA breakeven by Q4 and plans further expansion into mRNA and gene therapies.
Twist Bioscience Slides: Corporate presentation
Twist Bioscience has posted slides in relation to its latest quarterly earnings report, which was published on June 2, 2026.
Twist Bioscience to Present at William Blair 46th Annual Growth Stock Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder...
Twist Bioscience Transcript: Investor Day 2026
Industry-leading DNA synthesis and automation have enabled rapid expansion into AI-driven drug discovery, antibody engineering, and sustainability applications. Customer collaborations have driven major improvements in success rates, scale, and data generation, fueling strong revenue growth and positioning the platform for leadership in both healthcare and industrial biotechnology.
Twist Bioscience Slides: FY 2026
Twist Bioscience has posted slides in relation to its FY 2026 quarterly earnings report, which was published on May 21, 2026.
LenioBio and Twist Bioscience Enter into a Collaboration to Further Enable AI drug-discovery
DÜSSELDORF, Germany--(BUSINESS WIRE)--LenioBio GmbH, a TechBio company commercializing its ALiCE® cell-free protein expression platform, today announced a collaborative agreement with Twist Bioscience...
Twist Bioscience Earnings Call Transcript: Q2 2026
Q2 revenue grew 19% YoY to $110.7M, with gross margin expanding to 51.6% and strong growth in DNA synthesis, protein solutions, and NGS. Fiscal 2026 guidance was raised, with adjusted EBITDA breakeven expected in Q4, driven by robust demand in AI-enabled drug discovery and diagnostics.
Twist Bioscience Earnings release: Q2 2026
Twist Bioscience released its Q2 2026 earnings on May 4, 2026, summarizing the period's financial results.
Twist Bioscience Slides: Q2 2026
Twist Bioscience has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on May 4, 2026.
Twist Bioscience Quarterly report: Q2 2026
Twist Bioscience has published its Q2 2026 quarterly earnings report on May 4, 2026.
Twist Bioscience Expands Clonal Genes Offering to Include Long and Complex Sequences
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today expanded its clonal genes portfolio with the early access l...